Class Action Lawsuit Filed Against uniQure N.V. by Pomerantz Law Firm with Important Deadlines Ahead

Investor Alert: Class Action Lawsuit Filed Against uniQure N.V.

On March 19, 2026, Pomerantz LLP announced a significant class action lawsuit against uniQure N.V., trading on NASDAQ under the ticker symbol QURE. This legal action is designed for investors who have suffered losses as a result of their investment in the company. For those affected, it's crucial to understand the steps that need to be taken, particularly as important deadlines approach.

The lawsuit centers on allegations of securities fraud and claims that uniQure, along with certain officers and directors, may have engaged in unlawful business practices that misled investors. Potentially impacted investors are urged to reach out to the firm's representative, Danielle Peyton, via email at [email protected] or by calling 646-581-9980, to express interest in joining the lawsuit. It is recommended that inquiries include the investor's mailing address, phone number, and details on the number of shares purchased to expedite the process.

Investors must act swiftly, as the window to appoint a Lead Plaintiff in the case closes on April 13, 2026, for those who purchased or acquired uniQure stock during the class period. Those interested can obtain a copy of the complaint via the Pomerantz website. The importance of this lawsuit was underscored when, on November 3, 2025, uniQure announced unfavorable feedback from the U.S. Food and Drug Administration (FDA) regarding its investigational gene therapy, AMT-130, aimed at treating Huntington's disease.

According to the press release from uniQure, the FDA suggested that previous data may not be sufficient for a Biologics License Application submission, a significant shift from prior communications. Consequently, this uncertainty regarding the timeline of the BLA submission led to a drastic decline in uniQure's stock price, which plummeted by over 49%, closing at $34.29 on that day.

Pomerantz LLP, renowned for its expertise in corporate, securities, and antitrust class action litigation, has a long history of fighting for victims of securities fraud and corporate misconduct. With offices in major cities including New York, Chicago, and London, the firm emphasizes its commitment to protecting shareholder rights and ensuring accountability from corporations and their officers. Founded by Abraham L. Pomerantz, an influential figure in this field, the firm continues to uphold its legacy of advocacy for investors.

It remains to be seen what the outcome of this lawsuit will be, but it serves as a critical reminder for investors to remain vigilant and informed about their rights and options in the wake of significant corporate announcements that may influence stock performance. Investors are encouraged to act quickly, given the impending deadlines related to this legal matter.

For more information about the class action lawsuit against uniQure N.V., and to verify the details of your potential claim, please visit www.pomerantzlaw.com.